EYP 651
Alternative Names: EYP-651Latest Information Update: 25 Aug 2023
At a glance
- Originator ENYO Pharma
- Class Anti-inflammatories; Urologics
- Mechanism of Action Farnesoid X-activated receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Kidney disorders
- Phase I Diabetic nephropathies
Most Recent Events
- 12 Jul 2023 Phase-I clinical trials in Diabetic nephropathies (PO), prior to July 2023 (Enyo pharma pipeline, July 2023)
- 12 Jul 2023 Phase-II clinical trials in Kidney disorders (PO), prior to July 2023 (Enyo pharma pipeline, July 2023)